EGA Announces Three External Senior Advisors to its Global Health Policy and Public Affairs Offering
May 2, 2023 — WASHINGTON D.C. — Edelman Global Advisory (EGA) today announced the expansion of its recently formed Global Health Policy and Public Affairs offering with the addition of three senior health advisors: Sara Radcliffe, Craig Kramer, and Jeff Kemprecos. The offering, announced in January and led by EGA Health Chair Joseph Damond, helps companies navigate the challenges of a complex health policy environment while anticipating and proactively addressing emerging developments and trends.
“Our new colleagues are three of the most globally respected health policy and government affairs experts, all of whom have extensive knowledge of health policy issues, but deep experience working in practical ways with governments, health-care companies, and other key stakeholders,” said EGA Health Chair, Joseph Damond. “As EGA continues to expand its global footprint and enhance its capabilities, the addition of these three advisors will enable EGA to keep pace with the needs of its clients in public affairs, policy, and government affairs.”
Sara Radcliffe will serve as EGA Senior Advisor. As former Executive Vice President of Health at Biotechnology Innovation Organization and former Chief Executive Officer of the California Life Sciences Association, Radcliffe is a nationally recognized expert on the impact of changes in regulatory, scientific, and reimbursement policy on the life sciences industry.
Craig Kramer, who will also serve as EGA Senior Advisor, is co-chair of the UN-affiliated mental health innovation working group and the US National Action Alliance for Suicide Prevention. Previously, Kramer was also Mental Health Ambassador for Johnson & Johnson, one of the world’s largest comprehensive healthcare companies.
Finally, Jeff Kemprecos joins EGA as a Senior Advisor following a long career in the global pharmaceutical industry, including his most recent role as Director of Communications, Government Affairs & Market Access at GSK. For more than 30 years, Kemprecos worked in the innovative biopharmaceutical industry, including in Eastern Europe, MENA, Latin America, and APAC.
The EGA Global Health Policy and Public Affairs offering is based out of Washington, D.C. with locations in the United States, Canada, Europe, APAC, Latin America, MENA, and India.
Sara Radcliffe is a nationally recognized expert on the impact of changes in regulatory, scientific, and reimbursement policy on the life sciences industry. She advocates for the acceleration of FDA approval of new drugs, devices, and diagnostics; a science-based regulatory environment; optimization of reimbursement for marketed products by public and private payers; policies to advance personalized medicine and emergency preparedness; and above all, health policy that maximizes biomedical innovation, patient safety, and patient access. She also develops strategies to maximize organizational efficiency and revenue growth, and expand public impact and influence.
Sara served as the founding President and CEO of the California Life Sciences Association (CLSA), the premier life sciences trade association for California. Prior to CLSA, Sara served as Executive Vice President, Health at the Biotechnology Innovation Organization (BIO) and as Senior Director, Biologics & Biotechnology, at the Pharmaceutical Research and Manufacturers of America (PhRMA). She began her career working in the Alliance and Technology Group at SmithKline Beecham.
Craig Kramer is co-chair of the UN-affiliated mental health innovation working group and the US National Action Alliance for Suicide Prevention.
Previously, until December 2022, Craig was Mental Health Ambassador for Johnson & Johnson, the world’s largest comprehensive healthcare company. In that capacity, Craig chaired Johnson & Johnson’s Global Campaign for Mental Health, which worked with partners around the world to transform mental health care by raising awareness, reducing stigma, promoting research, improving access, and ensuring better patient outcomes. Key initiatives included an international advocacy network, a “global fund” for research, a coalition of employee resource groups, and a world leaders’ coalition to champion proven, scalable reforms, including “next-in-class” workplace mental health practices.
Prior to this role, Craig held a variety of positions in global corporate and government affairs at Johnson & Johnson and worked as a lawyer in the U.S. Congress, a Washington, D.C., law firm, and an international human rights organization. Craig is a graduate of Princeton University's School of Public & International Affairs, the University of Michigan Law School, and Harvard Business School. He serves as a board member with mental health nonprofits like Project HEAL for eating disorders, DMAX Foundation for college students, Trinity Counseling Service for the uninsured, Mental Health Center of Denver WellPower for community and criminaljustice services, and On Our Sleeves for children and families.
Jeffrey P. Kemprecos, BA, MA, MIB, is the Principal at Biopharma Vision Advisors, LLC, a consultancy specializing in advising innovative biopharmaceutical companies on how to navigate healthcare systems, enhance corporate reputation, and shape public policy to advance human health.
Prior to establishing Biopharma Vision Advisors, Jeff worked as Director of Communications, Government Affairs & Market Access at GSK, a globally-leading healthcare company. In that role, Jeff built a best-in-class government affairs, communications, and market access team, established new business lines exceeding $200M, and led GSK and the regional industry trade association policy advocacy across a wide range of health and pharmaceutical issues. The scope of his work includes healthcare reform, intellectual property and trade-related issues, access to innovative medicines and vaccines, healthcare financing and value of innovation, and regulatory harmonization. Policies and legislation affecting competition, investment, and innovation in the pharmaceutical sector constitute a primary focus. Public policy work comprises two complementary missions—advocating legislation, regulations and policies that advance human health and strengthen the innovative medicines sector.
Jeff has worked in the innovative biopharmaceutical industry across a variety of countries and regions for more than 30 years, including the Eastern Europe, Middle East, Africa, Latin America and Asia/Pacific regions, leading teams responsible for up to 140 countries. He has achieved extensive experience working with international organizations, and trade and business associations where he has held many leadership roles. In 2022, Jeff completed his second term as Chairman of the Intellectual Property Committee for the Pharmaceutical Research & Manufacturers Association in the Gulf (PHRMAG) and chaired the Department of Health Working Group. He served as a member of the U.K. Business Council’s Healthcare and Life Sciences Working Group and as representative from the pharmaceutical sector on the special council advising the Undersecretary at the Department of Health, Abu Dhabi.
ABOUT EDELMAN GLOBAL ADVISORY
Edelman Global Advisory (EGA), as part of Daniel J. Edelman Inc. (Edelman), is a boutique firm providing government affairs and business advisory services to help clients navigate today’s changing geopolitical and economic landscape. Based in Washington, D.C., EGA has deep expertise on the ground in the U.S. and Canada, APAC, MENA, Europe, Latin America, and India. EGA’s team members work seamlessly with Edelman’s other 6,000+ world-class communications professionals to deliver truly integrated client services.